Polynucleotides in Dubai

Polynucleotides in Dubai are now offered by a great many clinics, yet the term is used loosely enough that patients comparing quotes are often comparing quite different products. This page is written for readers who already know the basics and want the clinical detail: what distinguishes PN from PDRN, why molecular weight matters, how injection technique changes the result, and what the published evidence actually supports. Dr Sarah Magdy will go through the same detail at our Mirdif clinic. For an assessment, call 04 268 8226 or message us on WhatsApp at +971 56 598 6039.

PN and PDRN Are Not Interchangeable

Both terms describe purified DNA fragments, usually of salmon origin, but they behave differently in the skin and the distinction is clinically meaningful.

PDRN stands for polydeoxyribonucleotide. It consists of shorter, low-molecular-weight DNA fragments, and its proposed mechanism centres on receptor-level activity — specifically adenosine A2A receptor engagement, which is associated with anti-inflammatory signalling and tissue repair. Accordingly, PDRN products are often positioned around healing and inflammation.

PN, or polynucleotides, comprises longer chains. Beyond signalling, these longer molecules bind water and behave somewhat like a hydrogel within the dermis, providing a scaffolding and hydrating effect alongside their biological activity. Consequently, PN products tend to be positioned around skin quality, elasticity and structural support.

In practice, the two overlap considerably, and several commercial products sit between the categories. Nevertheless, when a clinic quotes you a price, asking whether the product is PN or PDRN class tells you far more than the brand name alone. We use and will confirm the classification at your consultation.

Why Molecular Weight and Concentration Matter

Two products can both be labelled polynucleotide and still differ substantially in effect, because chain length and concentration vary between manufacturers. Longer chains generally provide more of the water-binding, scaffolding behaviour. Higher concentrations, meanwhile, tend to produce more visible post-injection bumps and a longer settling period.

Therefore product selection is a clinical decision rather than a matter of stocking whichever brand is trending. For thin periorbital skin, for instance, a lighter formulation placed superficially is usually preferable to a dense one. For the neck or for skin needing more structural support, a longer-chain product may serve better.

What the Published Evidence Supports

The literature is growing but remains modest in scale, so it is worth being precise about what exists. Most published work consists of small clinical studies and split-face comparisons, together with laboratory investigation of mechanism. Reported outcomes centre on improvements in skin hydration, elasticity and patient-assessed skin quality, along with some evidence for adjunctive benefit in acne scarring and post-procedure recovery.

What the evidence does not yet provide is large randomised trials, standardised comparison between products, or long-term follow-up data. Consequently, we describe polynucleotides as a reasonable, well-tolerated option supported by encouraging early evidence — not as an established treatment on par with, say, microneedling for scarring or hyaluronic acid filler for volume. Patients who ask us for the evidence position get this answer rather than a marketing one.

Indications by Treatment Area

Injection Technique and Why It Changes the Outcome

Two clinicians using the same product can produce noticeably different results, and technique accounts for much of that. Several variables are in play.

• Depth — intradermal placement suits skin-quality goals, whereas deeper placement behaves differently and is not always appropriate for this product class.
• Distribution — micro-droplet technique across a treatment grid generally gives more even improvement than fewer, larger deposits.
• Density — the number of injection points per area, which is planned against the product concentration to avoid excessive bumping.
• Needle versus cannula — chosen by area, with vascular anatomy and bruising risk informing the decision.
• Volume per zone — distributed according to skin thickness rather than divided equally across the face.

Because of these variables, it is entirely reasonable to ask a clinic how they intend to treat a given area, not merely which product they will use.

Sequencing With Other Treatments

Polynucleotides are frequently one element of a broader plan, and the order matters more than patients expect. As a general approach, we allow appropriate intervals around resurfacing and needling rather than performing everything at once, and we avoid combining several inflammatory treatments in a single sitting.

Regarding specific combinations: with microneedling, polynucleotides are often used to support recovery, and the protocol for that is set out on our Dermapen with salmon DNA page. With botulinum toxin and filler, sequencing is usually straightforward but still planned deliberately. With laser or peels, spacing depends on the depth of the resurfacing performed. Where a patient has a wedding or event in view, we work backwards from the date so the course completes with room to spare.

Where It Sits Against Other Injectable Categories

Note that polynucleotides do not substitute for any of the others. Where volume has genuinely been lost, filler is the correct tool, and no quantity of skin-quality treatment will address hollowing. Our mesotherapy page covers the hydration-focused alternatives, while our salmon DNA guide answers the more general questions patients ask about this treatment.

On Scalp Use

Polynucleotides are used on the scalp for hair thinning, and enquiries continue to rise. Our position remains that diagnosis precedes treatment. Iron deficiency, thyroid dysfunction, hormonal change, medication effects, nutritional gaps, telogen effluvium and androgenetic alopecia present with overlapping appearances but require entirely different management. Injecting a scalp without establishing which of these applies is unlikely to represent good value. So we recommend a dermatology consultation with appropriate blood work first, after which scalp treatment can be planned rationally if it remains indicated.

Treatment Course and Expected Timeline

A standard course comprises around three sessions at two to four week intervals, followed by maintenance at roughly six to twelve month intervals depending on the product and the area treated. Improvement is progressive: most patients register a change from the second session, with continued benefit accruing for several weeks after completion.

Regarding recovery, expect papules at each injection point resolving over 24 to 72 hours, with periorbital treatment sometimes taking slightly longer. Bruising is possible, particularly on the neck and around the eyes. Plan any social or professional commitments with that in mind.

Contraindications and Precautions

Treatment is avoided in pregnancy and breastfeeding, and in the presence of active infection or inflammatory dermatosis at the intended site. Additionally, the following require discussion before proceeding: fish or seafood allergy, coagulopathies, anticoagulant and antiplatelet therapy, active autoimmune disease, immunosuppression, keloid tendency, and recent systemic isotretinoin. A full medication and supplement history is taken at assessment, since several over-the-counter supplements affect bruising.

Cost and Course Planning

Pricing depends on the product class, the volume used, the area treated and the number of sessions. Since this is a course-based treatment, we quote the course rather than a single session, and we set out what maintenance will involve so the ongoing commitment is clear from the outset. Call 04 268 8226 for current fees. As a cosmetic treatment, it is not covered by insurance.

Book an Assessment in Mirdif, Dubai

Book an Assessment or call 04 268 8226. You can also browse aesthetics in Dubai or reach us via the contact page.

Frequently Asked Questions

What is the difference between PN and PDRN?

PDRN consists of shorter, low-molecular-weight DNA fragments, with a proposed mechanism centred on adenosine A2A receptor activity and anti-inflammatory signalling. PN comprises longer chains that additionally bind water and provide a hydrogel-like scaffolding effect in the dermis. They overlap in practice, though the distinction is worth asking about when comparing products.

Does molecular weight really change the result?

It influences behaviour in the skin, yes. Longer chains contribute more water-binding and scaffolding effect, whereas higher concentrations tend to produce more visible post-injection papules and a longer settling time. Product choice is therefore matched to the area and the skin being treated.

How is it injected?

Typically by intradermal micro-droplet technique across a planned grid, with depth, density and volume adjusted by area. Needle or cannula is selected according to the region and its vascular anatomy. Technique accounts for a meaningful part of the outcome, so it is fair to ask how a clinic intends to treat you.

How long do the papules last?

Generally 24 to 72 hours, occasionally a little longer in the periorbital area. Bruising is possible on the neck and around the eyes. Consequently, do not schedule treatment immediately before a significant commitment.

How does it compare with a hyaluronic acid skin booster?

Both improve hydration. Polynucleotides additionally aim to support the repair environment and elasticity, which is why they are often selected for thin or crepey skin. For straightforward dehydration, however, a hyaluronic acid booster may be sufficient and less expensive.

Can it be combined with filler or toxin in one appointment?

Sometimes, though we plan sequencing deliberately rather than compressing multiple inflammatory treatments into a single sitting. Intervals around laser, peels and needling depend on the depth of the other treatment.

Is there evidence for acne scarring?

There is some evidence for adjunctive benefit, meaning alongside needling or resurfacing rather than instead of it. Microneedling remains the better-evidenced primary treatment for atrophic scarring, and we would build a scar plan around that.

How many sessions and how often?

Around three sessions at two to four week intervals, then maintenance every six to twelve months depending on product and area. Improvement is progressive rather than immediate.

Which product do you use, and is it registered?

We will tell you the product, its class and its registration status at consultation, and show you the packaging. Any clinic should be willing to do the same.

Who should not have polynucleotide treatment?

It is avoided in pregnancy and breastfeeding, and where there is active infection or inflammatory skin disease at the site. Fish allergy, coagulopathies, anticoagulant therapy, autoimmune disease, immunosuppression, keloid tendency and recent systemic isotretinoin all require discussion first.

What are your opening hours?

We are open from 11:00 AM to 8:00 PM. Please book ahead on 04 268 8226.

This page is general clinical information, not medical advice or a diagnosis. Suitability, product selection and technique are determined at an in-clinic assessment. Polynucleotide treatment carries risks including injection-point papules, swelling, bruising, infection and, rarely, allergic reaction. Results vary between individuals and no outcome can be guaranteed. The published evidence base remains limited in scale, and this treatment does not add volume, lift the face or substitute for filler where volume has been lost.